PolyPid (PYPD) Shares Outstanding (2019 - 2026)
PolyPid (PYPD) posted Shares Outstanding (Entity) of $21.9 million for Q1 2026, up 20.44% sequentially from $18.2 million in Q4 2025, and up 115.13% YoY from $10.2 million in Q1 2025.
PolyPid (PYPD) Shares Outstanding (2019 - 2026) Analysis & Trends
PolyPid has reported Shares Outstanding (Entity) for 8 years, with the latest figure at $21.9 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 115.13% year-over-year to $21.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.9 million (up 115.13% YoY) and the FY2025 annual result came in at $18.2 million, up 207.87% from the prior year.
- Shares Outstanding (Entity) climbed to $21.9 million in Q1 2026 per PYPD's latest filing, from $18.2 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $21.9 million in Q1 2026 and troughed at $648960.0 in Q1 2022.
- A 5-year average of $6.7 million and a median of $4.8 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) rose 3.87% in 2022, then jumped 569.56% in 2024.
- Over 5 years, Shares Outstanding (Entity) stood at $661662.0 in 2022, then soared by 149.91% to $1.7 million in 2023, then soared by 257.59% to $5.9 million in 2024, then soared by 207.87% to $18.2 million in 2025, then rose by 20.44% to $21.9 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $21.9 million, $18.2 million, and $20.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | PolyPid | 113.30 Mn | 106.53 Mn | - | 22.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.92 Mn |
| Mar 31, 2026 | 21.92 Mn |
| Dec 31, 2025 | 16.35 Mn |
| Sep 30, 2025 | 20.05 Mn |
| Jun 30, 2025 | 12.84 Mn |
| Mar 31, 2025 | 11.75 Mn |
| Dec 31, 2024 | 5.91 Mn |
| Sep 30, 2024 | 6.36 Mn |
| Jun 30, 2024 | 5.02 Mn |
| Mar 31, 2024 | 4.69 Mn |
| Dec 31, 2023 | 1.40 Mn |
| Sep 30, 2023 | 1.65 Mn |
| Jun 30, 2023 | 1.48 Mn |
| Mar 31, 2023 | 716,483.00 |
| Dec 31, 2022 | 647,492.00 |
| Sep 30, 2022 | 653,175.00 |
| Jun 30, 2022 | 650,110.00 |
| Mar 31, 2022 | 631,152.00 |
| Dec 31, 2021 | 623,989.00 |
| Sep 30, 2021 | 625,156.00 |